Skip to main content

Table 6 Univariate analysis of characteristics and osteosarcoma patient survival based on the log-rank test

From: Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

Clinicopathologic data

Case number

Disease-free survival (months)

Overall survival (months)

Mean

SD

95%CI

P value

Mean

SD

95%CI

P value

Sex

 Male

38

53.81

5.59

42.85–64.76

NS

71.04

4.39

62.44–79.65

NS

 Female

22

32.39

5.13

22.34–42.44

 

53.81

6.59

40.91–66.72

 

Age (years)

 < 18

26

37.42

5.43

26.79–48.06

NS

51.51

4.42

42.84–60.17

NS

 ≥ 18

34

51.96

5.91

40.37–63.54

 

68.56

5.00

58.75–78.36

 

Tumor location

 Tibia or femur

40

49.67

5.56

38.77–60.57

NS

67.47

4.52

58.60–76.33

NS

 Other location

20

46.15

7.57

31.32–60.98

 

60.55

6.86

47.10–74.00

 

Histologic subtype

 Conventional

55

49.20

4.77

39.86–58.54

NS

66.42

3.97

58.64–74.20

NS

 Special

5

40.20

10.96

18.71–61.69

 

55.40

14.72

26.54–84.26

 

Tumor size (cm)

 < 5

23

65.17

6.63

52.18–78.17

0.006

77.91

4.36

69.38–86.45

0.015

 ≥ 5

37

36.39

4.97

26.65–46.12

 

55.98

4.96

46.26–65.71

 

Enneking staging

 I-IIA

21

70.05

6.27

57.75–82.34

0.001

79.71

4.25

71.39–88.04

0.010

 IIB

39

36.42

5.08

26.46–46.38

 

56.54

4.87

47.00–66.07

 

Response to chemotherapya

 Good

28

63.86

6.14

51.83–75.89

0.002

79.11

3.76

71.74–86.48

0.001

 Poor

32

32.84

4.91

23.22–42.47

 

51.56

5.42

40.94–62.18

 
  1. SD standard deviation, CI confidence interval, NS no significance
  2. aGood: tumor necrosis ≥ 90%; poor: tumor necrosis < 90%